卡立普嗪辅助治疗氯氮平反应欠佳：两例报告
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.
作者信息
Berardis Domenico De, Rapini Gabriella, Olivieri Luigi, Giardini Agostina, Lauretis Ida De, Serroni Nicola, Orsolini Laura, Fornaro Michele, Iasevoli Felice, Trotta Sabatino, Cottura Paolo, Vellante Federica, Alessandrini Marco, Giannantonio Massimo Di
机构信息
National Health Service, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital "G. Mazzini," Teramo, Italy.
Department of Neurosciences and Imaging, Chair of Psychiatry, University "G. d'Annunzio," Chieti, Italy.
出版信息
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178. doi: 10.9758/cpn.2021.19.1.174.
Abstract
Cariprazine is a novel antipsychotic drug that exerts partial agonism of dopamine D/D receptors with preferential binding to the D receptor, antagonism of 5HT receptors, and partial agonism of 5HT. Currently, cariprazine has shown clinical efficacy in patients with schizophrenia and with bipolar disorder, as well as adjunctive treatment in patients with Major Depressive Disorder (MDD) and drug-resistant MDD. In the present case series, we report on two patients with treatment-resistant schizophrenia and partial response to clozapine who benefit from combination with cariprazine. The effects of cariprazine combination were remarkable also concerning the adverse metabolic effects of clozapine.
摘要
卡立哌嗪是一种新型抗精神病药物，它对多巴胺D2/D3受体具有部分激动作用，对D3受体具有优先结合力，对5-HT2A受体具有拮抗作用，对5-HT1A受体具有部分激动作用。目前，卡立哌嗪已在精神分裂症患者、双相情感障碍患者中显示出临床疗效，以及在重度抑郁症（MDD）患者和难治性MDD患者中的辅助治疗效果。在本病例系列中，我们报告了两名难治性精神分裂症患者，他们对氯氮平有部分反应，联合使用卡立哌嗪后获益。卡立哌嗪联合使用在改善氯氮平的不良代谢效应方面也有显著效果。
相似文献
1
Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases.卡立普嗪辅助治疗氯氮平反应欠佳：两例报告
Clin Psychopharmacol Neurosci. 2021 Feb 28;19(1):174-178. doi: 10.9758/cpn.2021.19.1.174.
2
Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review.卡立普嗪联合氯氮平治疗阴性症状：病例系列及文献综述
Ther Adv Psychopharmacol. 2022 Jan 28;12:20451253211066642. doi: 10.1177/20451253211066642. eCollection 2022.
3
The Novel Antipsychotic Cariprazine (RGH-188): State-of-the-Art in the Treatment of Psychiatric Disorders.新型抗精神病药物卡立普嗪（RGH-188）：精神疾病治疗的最新进展
Curr Pharm Des. 2016;22(33):5144-5162. doi: 10.2174/1381612822666160701084447.
4
Using Cariprazine to Ameliorate Negative Symptoms and Metabolic Side Effects of Clozapine and Paliperidone - Clinical Cases.使用卡立普嗪改善氯氮平和帕利哌酮的阴性症状及代谢副作用——临床病例
Neuropsychiatr Dis Treat. 2022 Jun 9;18:1145-1149. doi: 10.2147/NDT.S343747. eCollection 2022.
5
Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.卡立普嗪用于治疗精神分裂症：对这种优先作用于多巴胺D3的D3/D2受体部分激动剂的综述
Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109.
6
Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.卡立普嗪，一种口服活性D2/D3受体拮抗剂，用于潜在治疗精神分裂症、双相躁狂和抑郁症。
Curr Opin Investig Drugs. 2010 Jul;11(7):823-32.
7
Cariprazine in Three Special Different Areas: A Real-World Experience.卡立普嗪在三个特殊不同领域的应用：真实世界经验
Neuropsychiatr Dis Treat. 2021 Dec 7;17:3581-3588. doi: 10.2147/NDT.S335332. eCollection 2021.
8
The Role of Dopamine D Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens.卡利拉嗪诱导的大鼠海马和伏隔核神经递质外排中多巴胺 D 受体部分激动剂的作用。
J Pharmacol Exp Ther. 2019 Nov;371(2):517-525. doi: 10.1124/jpet.119.259879. Epub 2019 Sep 11.
9
Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression.卡立普嗪，一种新型的口服活性多巴胺D2/3受体部分激动剂，用于治疗精神分裂症、双相躁狂症和抑郁症。
Expert Rev Neurother. 2013 Nov;13(11):1141-59. doi: 10.1586/14737175.2013.853448.
10
Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome.长期使用氯氮平治疗且难治性精神分裂症患者加用卡立普嗪：两例精神病性恶化和匹萨综合征病例
Clin Psychopharmacol Neurosci. 2022 May 31;20(2):398-401. doi: 10.9758/cpn.2022.20.2.398.
引用本文的文献
1
Cariprazine and clozapine: a systematic review of a promising antipsychotic combination for treatment-resistant schizophrenia.卡立哌嗪与氯氮平：对一种有前景的用于治疗难治性精神分裂症的抗精神病药物组合的系统评价
Int J Neuropsychopharmacol. 2025 Aug 1;28(8). doi: 10.1093/ijnp/pyaf053.
2
Cariprazine in the management of emotionally unstable personality disorder in female patients: a case series.卡立普嗪治疗女性情绪不稳定型人格障碍：病例系列
Front Psychiatry. 2024 Jul 8;15:1421698. doi: 10.3389/fpsyt.2024.1421698. eCollection 2024.
3
The management of patients with predominant negative symptoms in Slovakia: A 1-year longitudinal, prospective, multicentric cohort study.斯洛伐克以阴性症状为主的患者管理：一项为期 1 年的纵向、前瞻性、多中心队列研究。
Eur Psychiatry. 2024 May 23;67(1):e44. doi: 10.1192/j.eurpsy.2024.1757.
4
Cariprazine augmentation in a patient with clozapine-resistant schizophrenia.卡立哌嗪辅助治疗氯氮平抵抗性精神分裂症患者
Ind Psychiatry J. 2023 Nov;32(Suppl 1):S279-S280. doi: 10.4103/ipj.ipj_208_23. Epub 2023 Nov 30.
5
Cariprazine augmentation of clozapine in schizophrenia-a retrospective chart review.卡立普嗪增强氯氮平治疗精神分裂症的疗效——一项回顾性病历审查
Front Pharmacol. 2024 Jan 4;14:1321112. doi: 10.3389/fphar.2023.1321112. eCollection 2023.
6
Therapeutic Appropriateness of Cariprazine in the Management of Schizophrenia: Experts' Opinion using a Delphi Approach.卡利拉嗪治疗精神分裂症的适宜性：德尔菲法专家意见。
Curr Neuropharmacol. 2023;21(11):2206-2216. doi: 10.2174/1570159X21666230719162023.
7
Lurasidone Augmentation of Clozapine in Schizophrenia-Retrospective Chart Review.氯氮平联合鲁拉西酮治疗精神分裂症——回顾性病历审查
Brain Sci. 2023 Mar 4;13(3):445. doi: 10.3390/brainsci13030445.
8
Cariprazine - an Alternative Treatment for Clozapine-resistant Schizophrenia?卡立普嗪——氯氮平难治性精神分裂症的替代治疗方法？
Clin Psychopharmacol Neurosci. 2023 Feb 28;21(1):202-206. doi: 10.9758/cpn.2023.21.1.202.
9
Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?精神分裂症患者中对氯氮平治疗方案无反应或不耐受时使用第三代抗精神病药物：证据是什么？
Front Psychiatry. 2022 Nov 29;13:1069432. doi: 10.3389/fpsyt.2022.1069432. eCollection 2022.
10
Efficacy and safety of cariprazine augmentation in patients treated with clozapine: a pilot study.卡立普嗪增效治疗氯氮平治疗患者的疗效与安全性：一项试点研究。
Ther Adv Psychopharmacol. 2022 Nov 21;12:20451253221132087. doi: 10.1177/20451253221132087. eCollection 2022.
本文引用的文献
1
Rapid improvement of obsessive-compulsive disorder associated with schizophrenia with cariprazine add-on in a subject under paliperidone long-acting injection: a case report.卡利拉嗪添加治疗合并精神分裂症的强迫症快速起效：1 例个案报告。
Int Clin Psychopharmacol. 2020 Mar;35(2):113-118. doi: 10.1097/YIC.0000000000000284.
2
3
The Role of Dopamine D Receptor Partial Agonism in Cariprazine-Induced Neurotransmitter Efflux in Rat Hippocampus and Nucleus Accumbens.卡利拉嗪诱导的大鼠海马和伏隔核神经递质外排中多巴胺 D 受体部分激动剂的作用。
J Pharmacol Exp Ther. 2019 Nov;371(2):517-525. doi: 10.1124/jpet.119.259879. Epub 2019 Sep 11.
4
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.新型抗精神病药物的特异性特征：鲁拉西酮、布瑞哌唑、卡利拉嗪和卢美哌隆的临床相关综述。
Eur Neuropsychopharmacol. 2019 Sep;29(9):971-985. doi: 10.1016/j.euroneuro.2019.06.008. Epub 2019 Jun 27.
5
Neural Networks in Neurological and Psychiatric Diseases.神经系统疾病和精神疾病中的神经网络
Curr Pharm Des. 2019;25(4):374-375. doi: 10.2174/138161282504190516080951.
6
Metabolic Syndrome Reversal With Cariprazine.卡立普嗪逆转代谢综合征
J Clin Psychopharmacol. 2019 Jul/Aug;39(4):413-416. doi: 10.1097/JCP.0000000000001074.
7
A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients.对氯氮平/去甲氯氮平比值在成人患者治疗药物监测中的临床实用性进行综合评价和联合分析。
Expert Rev Clin Pharmacol. 2019 Jul;12(7):603-621. doi: 10.1080/17512433.2019.1617695. Epub 2019 May 31.
8
The role of dopamine D receptors in the mechanism of action of cariprazine.多巴胺 D 受体在卡利拉嗪作用机制中的作用。
CNS Spectr. 2020 Jun;25(3):343-351. doi: 10.1017/S109285291900083X. Epub 2019 Apr 23.
9
Cariprazine for the treatment of bipolar depression: a review.卡利拉嗪治疗双相抑郁障碍的研究进展。
Expert Rev Neurother. 2019 Apr;19(4):317-323. doi: 10.1080/14737175.2019.1580571. Epub 2019 Feb 20.
10
The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors.卡利拉嗪治疗精神分裂症阴性症状的疗效：阳性和阴性症状量表（PANSS）各单项和因子的事后分析。
Eur Psychiatry. 2019 May;58:1-9. doi: 10.1016/j.eurpsy.2019.01.015. Epub 2019 Feb 7.
Zotero 插件